- Healionics Corporation, a Seattle, WA-based private medical device company, closed a $4.7M equity financing
- The round was led by Keiretsu Capital
- The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest
- Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer means to access the bloodstream for dialysis in patients with kidney failure
- Healionics is a clinical-stage company addressing the need for means of bloodstream access to perform dialysis in patients with kidney failure
- The company also has a product pipeline based on its platform STAR® biomaterial, which has an ability to resist both infection and scarring, two problems that affect all implanted devices
